Opioid-Induced Constipation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Opioid-Induced Constipation (US)
Opioid-induced constipation (OIC) is a condition in which bowel movements are infrequent or incomplete because of opioid medications. The treatment of OIC relies on various prescription medications, including several agents approved for irritable bowel syndrome with constipation or chronic idiopathic constipation and used off-label. Amitiza and its generics are predominantly used in later lines of therapy, reflecting physicians’ tendency to reserve this treatment for patients who have failed OTC laxatives and other initial interventions. Established treatments for OIC like Linzess and Movantik have a relatively constant patient share, but drug-treatment rates are low because many patients opt for OTC therapies. As a result, drugs such as Symproic and Relistor, which are FDA-approved to treat OIC, struggle to gain market share. This therapy market is also characterized by low persistency and compliance rates. In this report, we offer insight into current prescribing trends for OIC in the United States based on real-world claims data.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed OIC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed OIC patients?
- How have Linzess and Symproic been integrated into the treatment algorithm, and what is their source of business?
- What percentage of OIC patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
- What percentage of OIC patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key companies: Allergan, Ironwood, Synergy Pharma, Takeda, Mallinckrodt, Alfasigma, AstraZeneca, Daiichi Sankyo, Salix Pharmaceuticals, Endo Pharma
Key drugs: Motegrity, Linzess, Ibsrela, Relistor, Symproic, Movantik, Amitiza and generics, Trulance, osmotic laxatives, stimulant laxatives
Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
Product enhancement
Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.
